Clinical Guidelines for Calcium-Sensing Disorders

Abstract

Calcium-sensing disorders encompass a spectrum of conditions characterized by dysregulation of calcium homeostasis, often resulting from genetic or acquired defects in the calcium-sensing receptor (CaSR) pathway. These disorders, including familial hypocalciuric hypercalcemia (FHH), autosomal dominant hypocalcemia (ADH), and related syndromes, present unique diagnostic and management challenges. This article provides a comprehensive, evidence-based review of their epidemiology, pathophysiology, clinical manifestations, diagnostic strategies, and current guideline-driven management. Emphasis is placed on recent advances in molecular diagnostics and emerging therapies, with practical insights for clinicians managing affected patients.

Introduction

Calcium homeostasis is critical for neuromuscular, skeletal, and cardiovascular function. The calcium-sensing receptor (CaSR), expressed primarily in the parathyroid glands and kidneys, is pivotal in regulating parathyroid hormone (PTH) secretion and renal calcium excretion. Mutations or functional alterations in CaSR and associated signaling pathways underlie a group of rare but clinically significant disorders. Increasing recognition of calcium-sensing disorders, driven by advances in genetic testing and biochemical assays, has enhanced the understanding of their pathophysiology and informed evidence-based therapeutic approaches. This review synthesizes recent developments and consensus guidelines to support best clinical practices.

Epidemiology / Disease Burden

Calcium-sensing disorders are rare, with familial hypocalciuric hypercalcemia (FHH) estimated to affect 1 in 78,000 individuals, while autosomal dominant hypocalcemia (ADH) is even less prevalent. Both disorders demonstrate autosomal dominant inheritance with high penetrance but variable expressivity. Sporadic cases, often due to de novo mutations, are increasingly identified through expanded genetic screening. Although the overall disease burden is low compared to more common calcium disorders such as primary hyperparathyroidism, misdiagnosis is frequent and can lead to inappropriate interventions, including unnecessary parathyroidectomy. Accurate epidemiological data remain limited due to underrecognition and diagnostic challenges.

Pathophysiology

The CaSR is a G-protein coupled receptor that senses extracellular calcium levels and modulates PTH secretion accordingly. Loss-of-function mutations in the CaSR gene cause FHH, characterized by reduced receptor sensitivity, inappropriate PTH secretion, and mild hypercalcemia with hypocalciuria. Conversely, gain-of-function mutations result in ADH, with excessive CaSR activation, suppressed PTH, and hypocalcemia with hypercalciuria. Other rare conditions, such as neonatal severe hyperparathyroidism (NSHPT) and acquired forms due to autoantibodies or medications, further expand the phenotypic spectrum. Understanding these molecular mechanisms is crucial for targeted diagnostic and therapeutic strategies.

Risk Factors

Genetic predisposition is the principal risk factor, with most cases arising from inherited or de novo mutations in the CaSR gene or related signaling proteins (GNA11, AP2S1). Family history of calcium disorders, especially with features of hyper- or hypocalcemia and altered urinary calcium excretion, should prompt consideration of a calcium-sensing disorder. Acquired forms may be associated with medications (e.g., lithium, thiazides), autoimmune conditions, or chronic kidney disease, which can perturb CaSR expression or function. Genetic counseling is recommended for affected families.

Clinical Features

The clinical presentation varies by disorder and mutation severity. FHH typically manifests as lifelong, mild hypercalcemia, often asymptomatic and incidentally discovered. Symptoms, when present, are nonspecific and may include fatigue, mild neurocognitive complaints, or nephrolithiasis. ADH presents with hypocalcemic symptoms such as muscle cramps, paresthesias, tetany, or, rarely, seizures. Hypercalciuria in ADH increases the risk of nephrocalcinosis and renal impairment. NSHPT is a neonatal emergency with profound hypercalcemia, bone demineralization, and failure to thrive. Recognizing these phenotypes is essential to avoid misdiagnosis and unnecessary interventions.

Diagnosis

Diagnosis relies on a combination of clinical assessment, biochemical testing, and genetic analysis. Key laboratory findings include serum calcium, PTH, and urinary calcium excretion (calcium/creatinine clearance ratio). FHH is characterized by elevated serum calcium, inappropriately normal or elevated PTH, and low urinary calcium excretion (CCCR <0.01). ADH shows low serum calcium, suppressed PTH, and elevated urinary calcium. Genetic sequencing of CaSR, GNA11, and AP2S1 genes confirms the diagnosis and facilitates family screening. Differential diagnoses include primary hyperparathyroidism, vitamin D disorders, and other causes of hyper- or hypocalcemia. Distinguishing FHH from primary hyperparathyroidism is particularly critical, as management strategies differ substantially.

Treatment & Management

Management is guided by disorder type, symptom severity, and risk of complications. FHH typically requires no treatment, as the condition is benign and non-progressive. Patient education and avoidance of unnecessary parathyroid surgery are essential. For ADH, treatment is reserved for symptomatic patients and may include oral calcium and active vitamin D analogs, balancing the risk of hypercalciuria and nephrocalcinosis. Thiazide diuretics may reduce urinary calcium excretion. NSHPT often necessitates urgent parathyroidectomy. Long-term surveillance for renal and skeletal complications is recommended across all conditions. Multidisciplinary care, including endocrinology, nephrology, and genetic counseling, optimizes outcomes.

Recent Advances / Emerging Therapies

Recent advances include the development of calcimimetic and calcilytic agents that modulate CaSR activity. Cinacalcet, a calcimimetic, has shown efficacy in reducing serum calcium in FHH with severe hypercalcemia and in select cases of NSHPT. Calcilytics, which antagonize CaSR, are under investigation for treating ADH and related hypocalcemic syndromes. Next-generation genetic testing allows for earlier and more accurate diagnosis, supporting personalized treatment. Ongoing clinical trials are evaluating the safety and efficacy of these agents, with the potential to expand therapeutic options for patients with refractory or severe disease phenotypes.

Guideline Recommendations

International guidelines, including those from the Endocrine Society and European Society of Endocrinology, emphasize the importance of accurate biochemical and genetic diagnosis to differentiate calcium-sensing disorders from other hyper- and hypocalcemic conditions. Parathyroid surgery is contraindicated in FHH. Genetic testing is recommended for index cases and at-risk family members. In ADH, individualized therapy should aim to alleviate symptoms while minimizing renal complications. Regular monitoring of serum and urinary calcium, renal function, and bone health is advised. Multidisciplinary coordination and patient education are central to long-term management.

Conclusion

Calcium-sensing disorders, though rare, represent an important subset of calcium metabolism disorders with distinctive genetic and clinical profiles. Accurate diagnosis, guided by biochemical and genetic findings, is critical to avoid mismanagement. While most cases are benign and require conservative management, emerging therapies hold promise for symptomatic and severe phenotypes. Ongoing research and guideline refinement will further enhance patient care and outcomes in this evolving field.